本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688368 证券简称：晶丰明源 公告编号：2025-065 上海晶丰明源半导体股份有限公司 关于向 2024 年限制性股票激励计划激励对象 授予预留部分限制性股票的公告 ? 预留部分限制性股票授予日：2025 年 8 月 26 日 上海晶丰明源半导体股份有限公司（以下简称"公司"）2024 年限制性股票 激励计划（以下简称"本激励计划"）规定的限制性股票预留部分授予条件已经 成就，根据公司 2024 年第二次临时股东大会授权，公司于 2025 年 8 月 26 日召 开的第三届董事会第三十次会议、第三届监事会第二十七次会议审议通过了《关 于向 2024 年限制性股票激励计划激励对象授予预留部分限制性股票的议案》，确 定以 2025 年 8 月 26 日为预留授予日，以 27.78 元/股（调整后）的授予价格向 符合授予条件的 53 名激励对象授予 54.54 万股限制性股票。现将有关事项说明 如下： 一、限制性股票授予情况 （一）本次限制性股票授予 ...

（记者 贾运可） 2024年1至12月份，晶丰明源的营业收入构成为：集成电路占比99.94%，其他业务占比0.06%。 每经头条（nbdtoutiao）——能给主人"打电话"的宠物智能手机也来了！宠物产业3000亿元市场大爆 发，行业上市公司"涨"声一片 每经AI快讯，晶丰明源（SH 688368，收盘价：103.1元）8月26日晚间发布公告称，公司第三届第三十 次董事会会议于2025年8月26日以现场与通讯结合方式召开。会议审议了《关于聘任公司董事会秘书的 议案》等文件。 截至发稿，晶丰明源市值为91亿元。 ...

上海晶丰明源半导体股份有限公司 第三届董事会第三十次会议决议公告 证券代码：688368 证券简称：晶丰明源 公告编号：2025-062 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海晶丰明源半导体股份有限公司（以下简称"公司"）第三届董事会第三 十次会议于 2025 年 8 月 22 日以电子邮件、专人送达等方式通知了全体董事，会 议于 2025 年 8 月 26 日以现场与通讯结合方式召开。 会议由董事长胡黎强先生主持，会议应参与表决董事 7 人，实际参与表决董 事 7 人。本次董事会会议的召集和召开程序符合有关法律、行政法规、部门规章、 规范性文件和《上海晶丰明源半导体股份有限公司章程》（以下简称"《公司章 程》"）的规定，作出的决议合法、有效。 二、董事会会议审议情况 经与会董事表决，审议通过了如下议案： （一）审议通过《关于调整 2024 年限制性股票激励计划授予价格的议案》 表决结果：同意 6 票，反对 0 票，弃权 0 票。关联董事孙顺根为公司 2024 年限制性股票激励计划的激 ...

证券代码：688368 证券简称：晶丰明源 公告编号：2025-063 上海晶丰明源半导体股份有限公司 第三届监事会第二十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 具 体 内 容 详 见 公 司 于 2025 年 8 月 27 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）上披露的《上海晶丰明源半导体股份有限公司关于调整 2024 年限制性股票激励计划授予价格的公告》。 （二）审议通过《关于向 2024 年限制性股票激励计划激励对象授予预留部 分限制性股票的议案》 一、监事会会议召开情况 上海晶丰明源半导体股份有限公司（以下简称"公司"）第三届监事会第二 十七次会议于 2025 年 8 月 22 日以电子邮件、专人送达等方式通知了全体监事， 会议于 2025 年 8 月 26 日以现场会议方式召开。 会议由监事会主席李宁先生主持，会议应参加表决监事 3 人，实际参加表决 监事 3 人。本次监事会会议的召集和召开程序符合有关法律、行政法规、部门规 章、规范性文件和《上海晶 ...

邮政编码：201203 联系电话：021-50278297 证券代码：688368 证券简称：晶丰明源 公告编号：2025-066 上海晶丰明源半导体股份有限公司 关于聘任董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海晶丰明源半导体股份有限公司（以下简称"公司"）董事会于 2025 年 会秘书的议案》。经公司董事长提名，董事会提名委员会对被提名人进行资格审 查，董事会同意聘任杨彪先生为公司董事会秘书（简历后附），任期自本次董事 会审议通过之日起至公司第三届董事会任期届满之日止。公司董事长、总经理胡 黎强先生不再代行董事会秘书职责。 杨彪先生已取得上海证券交易所科创板董事会秘书任职培训证明，具备履行 董事会秘书职责所需的专业知识及工作经验，其任职资格符合有关法律法规及规 范性文件的规定，不存在《中华人民共和国公司法》（以下简称"《公司法》"） 《上海证券交易所科创板股票上市规则》及《公司章程》等规定的不得担任上市 公司高级管理人员的情形。 杨彪先生联系方式如下： 联系地址：中国（上海）自由贸易试验区申 ...

Group 1: Zhaoyi Innovation - Zhaoyi Innovation reported good growth across all business lines in Q2 2024, with NOR Flash growing in the high single digits, niche DRAM growing over 50%, and MCU close to 20% [1] - The company expects significant revenue growth in niche DRAM in the second half of the year, with contract prices continuing to rise [1] - The demand for NOR Flash is increasing due to a rise in electronic product code volume, while supply remains tight due to wafer manufacturing capacity constraints [1] Group 2: Teabo Bio - Teabo Bio is focusing on functional cure for hepatitis B through a combination of different mechanism drugs with interferons and nucleoside analogs [2] - The company aims to provide comprehensive management of hepatitis B through a wide-reaching clinical cure network [2] - Collaboration with Ligos is underway to explore reinfection control after clearing infected cells [2] Group 3: Ruijie Networks - Ruijie Networks saw significant revenue growth in data center products, primarily driven by internet clients, with over 90% of revenue coming from this sector [3] - The company anticipates continued strong demand for cloud computing infrastructure in the second half of the year [3] - The gross margin for data center products is relatively low (15%-20%), while margins in enterprise and SMB markets have improved [3] Group 4: Trina Solar - Trina Solar is focusing on maintaining fair competition in the photovoltaic industry and promoting healthy development [4] - The company aims for over 8GWh in the storage segment for the year, with an increasing proportion of overseas orders [4] - The demand in the U.S. market is accelerating, leading to increased component prices and optimized supply chains [4] Group 5: Liangxin Co. - Liangxin Co. has segmented its data center business into three main areas: internet enterprises, operators, and individual projects, with a focus on HVDC and UPS [5] - The company is expected to continue its efforts in digital energy and infrastructure despite a potential slowdown in the renewable energy sector [5] - The gross margin for overseas business has slightly decreased compared to the previous year [5] Group 6: Baillie Tianheng - Baillie Tianheng is advancing three key overseas clinical trials for treating triple-negative breast cancer, EGFR-mutant non-small cell lung cancer, and urothelial carcinoma [6] - The company has submitted its first nuclear medicine candidate drug for domestic IND application [6] - R&D expenses reached 1.038 billion yuan by mid-year, with expectations for future clinical research costs to increase [6] Group 7: Jingfeng Mingyuan - Jingfeng Mingyuan has achieved an increase in overall gross margin through cost reduction and efficiency improvements [7] - The company is expanding its market presence in smart LED lighting products despite a decline in sales and prices in traditional LED lighting [7] - The high-performance computing power supply chip business has seen rapid growth, with products entering large-scale sales [7] Group 8: Chipone - Chipone is providing various customized hardware and software solutions in the AI field, serving multiple international giants [8] - The company has a high percentage of R&D personnel, with 89.31% of staff engaged in research and development [8] - Chipone is advancing Chiplet technology and has achieved success in designing high-performance automotive chips [8] Group 9: Xiasha Precision - Xiasha Precision reported a 30.77% increase in revenue for the first half of 2025, but a 41.87% decline in net profit due to price competition and rising costs [9] - The company plans to expand its product line in joint modules and increase R&D investment [9] - A new factory in Vietnam is under trial production, with plans to expand into overseas markets [9] Group 10: Lepu Medical - Lepu Medical's subsidiary focuses on elderly care services and has developed a facial filler product that has received regulatory approval [10] - The company is advancing AI products that monitor vital signs through various hardware applications [10] - Lepu Medical has a significant asset management scale, ranking 14th among 210 in public fund management [10]

从资金流向来看，8月25日主力资金净流入935.10万元，占流通市值的0.1%。近五日主力资金累计净流 出3710.88万元，占流通市值的0.41%。 风险提示：投资有风险，入市需谨慎。本文所载信息仅供参考，不构成投资建议。 晶丰明源主营业务为模拟及混合信号集成电路的研发、设计和销售。公司产品广泛应用于LED照明、家 电、电源管理等领域。2025年半年度报告显示，公司实现销售收入7.31亿元，归属于上市公司股东的净 利润1576.20万元，较上年同期增加4626.96万元，同比上升151.67%。 8月25日公司发布公告称，在8月18日至22日期间接待了中信建投证券、交银基金、国泰基金等多家机构 调研。调研内容主要围绕公司半年度业绩情况展开。数据显示，近一年来公司共接待403家机构641次调 研。 截至2025年8月25日收盘，晶丰明源股价报102.59元，较前一交易日上涨0.01元，涨幅0.01%。当日开盘 价为104.24元，最高触及106.58元，最低下探101.91元，成交量为31799手，成交额达3.30亿元。 ...

Core Viewpoint - The article discusses the acquisition of Easy Charge Technology by Shanghai Jingfeng Mingyuan Semiconductor Co., Ltd. for 3.283 billion RMB (approximately 457 million USD) to enhance its product portfolio and competitiveness in the semiconductor industry [3][8]. Group 1: Company Overview - Shanghai Jingfeng Mingyuan, established in 2008, specializes in power management and control driver chips, with applications in various sectors including home appliances, mobile phones, and automotive [5][7]. - Easy Charge Technology, founded in 2016, is a leading provider of power management solutions, focusing on high-performance analog chips and mixed-signal integrated circuits, including wireless charging chips [5][10]. Group 2: Acquisition Details - The acquisition aims to strengthen Jingfeng Mingyuan's position in the "hard technology" sector and enhance its international competitiveness by integrating Easy Charge's resources [8][19]. - The transaction is characterized by a high premium, with an estimated valuation of Easy Charge at 3.29 billion RMB, reflecting a premium rate of 260.08% [16][17]. Group 3: Financial Performance - Easy Charge has reported losses in recent years, with projected losses of 502 million RMB and 512 million RMB for 2023 and 2024, respectively, totaling over 1 billion RMB in losses [14][16]. - Jingfeng Mingyuan has also faced profitability challenges, with net losses reported in the past three years, although it achieved a revenue of 1.504 billion RMB in 2024, a year-on-year increase of 15.38% [18]. Group 4: Strategic Implications - The acquisition is expected to enhance product offerings in wireless charging and automotive electronics, leveraging Easy Charge's established customer base, including major brands like Samsung and BYD [19][20]. - Performance commitments have been set for Easy Charge's business segments from 2025 to 2027, ensuring minimum net profits and revenues, which may provide a framework for long-term value realization [20][21].

Core Insights - The Social Security Fund has disclosed its stock holdings as of the end of Q2, appearing in the top ten shareholders of 29 stocks on the Sci-Tech Innovation Board, with a total holding of 94.71 million shares valued at 4.23 billion yuan [1][2] Group 1: Stock Holdings - The Social Security Fund has newly entered 6 stocks and increased holdings in 8 stocks, while reducing holdings in 7 stocks, with 8 stocks remaining unchanged [1] - The stocks with the highest holdings by the Social Security Fund include Daotong Technology with 9.27 million shares, followed by Times Electric and ST Nuotai with 6.31 million and 5.72 million shares respectively [2][3] - The highest holding ratio is for Haitai Xinguang at 4.20%, followed by Aopumai at 4.00% [2] Group 2: Financial Performance - Among the stocks held by the Social Security Fund, 25 companies reported year-on-year net profit growth in the first half of the year, with Rongzhi Rixin showing the highest growth rate of 2063.42% [2] - Other notable profit growth includes Xinxing Microelectronics and Jingfeng Mingyuan, with increases of 261.78% and 151.67% respectively [2] Group 3: Market Performance - Stocks held by the Social Security Fund on the Sci-Tech Innovation Board have averaged a 22.67% increase since July [3] - The best-performing stock is Dingtong Technology, with a cumulative increase of 69.16%, followed by Yuandong Biology and Kaiyin Technology with increases of 54.02% and 39.07% respectively [3]

购买资产并募集配套资金报告书（草案） 摘要（修订稿） | 项目 | 交易对方 | | --- | --- | | 发行股份及支付 | 海南玮峻思投资合伙企业（有限合伙）等 名易冲科 50 | | 现金购买资产 | 技股东 | | 募集配套资金 | 不超过 35 名符合中国证监会规定的特定投资者 | 独立财务顾问 签署日期：二〇二五年八月 声 明 股票代码：688368 股票简称：晶丰明源 上市地点：上海证券交易所 上海晶丰明源半导体股份有限公司 发行股份及支付现金 本部分所述词语或简称与报告书摘要"释义"所述词语或简称具有相同含义。 一、上市公司声明 本公司及本公司全体董事、监事及高级管理人员保证上市公司及时、公平地披露 信息，保证报告书及其摘要内容的真实、准确、完整，不存在虚假记载、误导性陈述 或者重大遗漏，保证报告书所引用的相关数据的真实性和合理性，并对所提供信息的 真实性、准确性、完整性负相应的法律责任。 如本次交易所披露或提供的信息涉嫌虚假记载、误导性陈述或者重大遗漏，被司 法机关立案侦查或者被中国证监会立案调查的，在形成调查结论以前，不转让在该上 市公司拥有权益的股份，并于收到立案稽查通知的两个交易 ...